scholarly journals Racial/Ethnic Disparities in Length of Life after Dementia Diagnosis: an 18-Year Follow-up Study of Medicare Beneficiaries

2022 ◽  
Vol 8 ◽  
pp. 100179
Author(s):  
Yi Chen ◽  
Eileen Crimmins ◽  
Patricia Ferido ◽  
Julie M. Zissimopoulos
Author(s):  
Jamie Browning ◽  
Chi Chun Steve Tsang ◽  
Jim Y. Wan ◽  
Marie A. Chisholm-Burns ◽  
Samuel Dagogo-Jack ◽  
...  

Author(s):  
Hannah Gardener ◽  
Erica C. Leifheit ◽  
Judith H. Lichtman ◽  
Yun Wang ◽  
Kefeng Wang ◽  
...  

2021 ◽  
Author(s):  
Elena Tsoy ◽  
Rachel E. Kiekhofer ◽  
Elan L. Guterman ◽  
Boon Lead Tee ◽  
Charles C. Windon ◽  
...  

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S791-S791
Author(s):  
Elizabeth A Luth ◽  
David Russell

Abstract Hospice delivers care to a substantial and growing number of individuals with primary and comorbid dementia diagnoses. Dementia diagnosis and racial/ethnic minority status are risk factors for hospice disenrollment. However, little research examines racial/ethnic disparities and other risk factors for hospice disenrollment among hospice patients with dementia. This paper uses multinomial logistic regression to explore sociodemographic and functional status risk factors for hospice disenrollment among 3,949 home hospice recipients with primary or comorbid dementia. Results indicate that patients with a primary dementia diagnosis, racial/ethnic minority groups, and those higher functional status have elevated risk of disenrollment due to hospitalization, disqualification, and electively leaving hospice care. Additional research is needed to understand why primary dementia diagnosis and underrepresented racial/ethnic status are associated with multiple kinds of hospice disenrollment so that hospice practice can be tailored to respond to the needs of these individuals.


Medical Care ◽  
2016 ◽  
Vol 54 (8) ◽  
pp. 765-771 ◽  
Author(s):  
Steven C. Martino ◽  
Marc N. Elliott ◽  
Katrin Hambarsoomian ◽  
Robert Weech-Maldonado ◽  
Sarah Gaillot ◽  
...  

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 54-54
Author(s):  
Jennifer Miles ◽  
Stephen Crystal ◽  
Peter Treitler ◽  
Richard Hermida

Abstract Although medication for addiction treatment (MAT) is known to be the most effective treatment for opioid use disorder (OUD), these medications are widely underutilized, especially among older adults and racial/ethnic minorities. Of the three main MAT modalities, Medicare covered buprenorphine and naltrexone in 2017; methadone was not covered until 2020. We examined MAT prescribing among elderly compared with non-elderly Medicare beneficiaries. Our sample was drawn from a ~40% random sample of 2017 Medicare beneficiaries with Part D coverage and was comprised of elderly beneficiaries (age 65+) with OUD (N=112,314) or who experienced opioid poisoning (N=9,657), and non-elderly Medicare beneficiaries (the Medicare disability population, age 0-64) with OUD (N=161,423) or opioid poisoning (N=13,591). MAT was underutilized in both Medicare populations, but especially in the elderly population. Of elderly beneficiaries with OUD, 5.1% and 0.8% were prescribed buprenorphine and naltrexone, respectively, compared to 15.5% and 2.3% among non-elderly. Among elderly beneficiaries with opioid poisoning, 3.1% and 0.8% were prescribed buprenorphine and naltrexone, respectively, compared to 10.1% and 3.2% in the non-elderly population. Sharp racial/ethnic disparities were identified within each age group. These findings highlight the need to expand access to MAT for Medicare beneficiaries, particularly older adults among whom underutilization is pronounced. Several recent Medicare policy changes have sought to address this issue, but continuing efforts and close monitoring are warranted in an effort to dramatically increase rates of treatment for elderly with opioid use disorder.


Sign in / Sign up

Export Citation Format

Share Document